Catabasis Pharmaceuticals, Inc.

Catabasis Pharmaceuticals, Inc.

Catabasis Pharmaceuticals, Inc.

Overview
Date Founded

2008

Headquarters

100 High Street,28th floor,Boston, MA 02110

Type of Company

Public

Employees (Worldwide)

20

Industries

Pharmaceuticals
Hospitals & Patient Services
Medical Support Services
Biotechnology

Company Description

Catabasis Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is edasalonexent, which is intended for the treatment of Duchenne muscular dystrophy. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.

Contact Data
Trying to get in touch with decision makers at Catabasis Pharmaceuticals, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Founder & Chief Executive Officer

Chief Financial Officer

Chief Legal Officer

Chief Commercial Officer

Chief Scientific Officer

Senior Vice President-Regulatory Affairs

Senior Vice President, Corporate Affairs

Director of Pharmacology

Director

Senior Scientist

Paths to Catabasis Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
You
Catabasis Pharmaceuticals, Inc.
Owners & Shareholders
Details Hidden

Fairmount Funds Management LLC is a private company headquartered in Philadelphia, PA, that provides investment advice. It was founded in 2016.

Details Hidden

Logos Global Management LP, a subsidiary of Logos Global Management Gp LLC, is a company headquartered in San Francisco, CA. The firm provides investment advice. It was founded in 2019 by Arsani Hany William and Graham Gordon Walmsley. Arsani Hany William has been the CEO since the inception date.

Details Hidden

Commodore Capital LP, a subsidiary of Commodore Capital Holdings LP, is an American company located in New York, NY, that provides investment advice. The firm was founded in 2019 by Robert Egen Turrell Atkinson.

Recent Transactions
Details Hidden

Catabasis Pharmaceuticals, Inc. purchases Quellis Biosciences, Inc. from Xontogeny LLC

Details Hidden

Catabasis Pharmaceuticals, Inc. issued USD Units Consisting of Common Stock and Warrants

Details Hidden

Catabasis Pharmaceuticals, Inc. issued USD Common Stock

Transaction Advisors
Escrow Agent

Advised onCatabasis Pharmaceuticals, Inc. issued USD Common Stock

Underwriter

Advised onCatabasis Pharmaceuticals, Inc. issued USD Common Stock

Legal Advisor

Advised onCatabasis Pharmaceuticals, Inc. issued USD Units Consisting of Common Stock and Warrants

Counsel

Advised onCatabasis Pharmaceuticals, Inc. issued USD Units Consisting of Common Stock and Warrants

Legal Advisor

Advised onCatabasis Pharmaceuticals, Inc. issued USD Common Stock

Associate

Advised onCatabasis Pharmaceuticals, Inc. purchases Quellis Biosciences, Inc. from Xontogeny LLC

Advisors & Consultants
Legal Advisor

Chair, Transactional Department at Wilmer Cutler Pickering Hale and Dorr LLP

Advisor

Chief Financial Officer at Boston Pharmaceuticals, Inc.

Key Stats and Financials As of 2020
Market Capitalization
$120M
Total Enterprise Value
$-4.61M
Earnings Per Share
$-12.2
Revenue
$0
Net Profit
$-37.3M
EBITDA
$-37.4M
Total Debt
$1.05M
Total Equity
$40.7M
TEVNet Income
0.12x
Debt TEV
-0.23x
Three Year Compounded Annual Growth Rate Of Revenue
-100%
Investors
Details Hidden

Professor at Harvard University - Harvard Medical School

Details Hidden

Senior Advisor at Frequency Therapeutics, Inc.

Details Hidden

Founder & Chief Executive Officer at Catabasis Pharmaceuticals, Inc.

Suppliers
Xencor, Inc. Biotechnology | Monrovia, CA

Xencor, Inc. engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.

Advisor Group Holdings, Inc. Holding Companies | Phoenix, AZ

Advisor Group Holdings, Inc. engages in the provision of banking and financial services. The company was founded in 2016 and is headquartered in Phoenix, AZ.

Competitors
Intellia Therapeutics, Inc. Biotechnology - Cambridge, MA

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Ionis Pharmaceuticals, Inc. Pharmaceuticals - Carlsbad, California

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.

CSL Limited Biotechnology - Parkville, VIC

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the CSL Behring and Seqirus segments. The CSL Behring segment provides plasma therapies and conducts early stage research on plasma and non plasma therapies. The Seqirus segment involves in the production of non-plasma biotherapeutic products and develops influenza related products. The company was founded on November 2, 1961 and is headquartered in Parkville, Australia.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Catabasis Pharmaceuticals, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Catabasis Pharmaceuticals, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Catabasis Pharmaceuticals, Inc..